GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Capital Expenditure

Abbisko Cayman (HKSE:02256) Capital Expenditure : HK$-7.94 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Abbisko Cayman's cash flow for capital expenditures for the six months ended in Dec. 2024 was HK$-2.6 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-7.94 Mil.

Abbisko Cayman Capital Expenditure Historical Data

The historical data trend for Abbisko Cayman's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Capital Expenditure Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial -4.78 -15.10 -25.40 -13.40 -7.90

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.65 -9.96 -3.44 -5.31 -2.64

Abbisko Cayman Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-7.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbisko Cayman Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Capital Expenditure
Comparable Companies
HKSE:02480 HKSE:02315 HKSE:01477 HKSE:02105 HKSE:01672 HKSE:06955 HKSE:06660 HKSE:02616 HKSE:02179 HKSE:09966 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
8ZD:Germany
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Website
https://www.abbisko.com
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.
Executives
Xu Yao-chang 2101 Beneficial owner
Qiming Corporate Gp Vi, Ltd. 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Chen Zhui 2501 Other
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Futu Trustee Limited 2301 Trustee
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Morgan Stanley 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Computershare Hong Kong Trustees Limited 2301 Trustee
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you

Abbisko Cayman Headlines

No Headlines